| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
|
Am J Hematol
|
2005
|
5.64
|
|
2
|
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
|
Leukemia
|
2009
|
4.91
|
|
3
|
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
|
Blood
|
2011
|
4.00
|
|
4
|
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
|
Blood
|
2011
|
3.07
|
|
5
|
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
|
J Clin Oncol
|
2010
|
2.58
|
|
6
|
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
|
Blood
|
2011
|
2.13
|
|
7
|
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
|
J Clin Oncol
|
2009
|
2.13
|
|
8
|
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
|
Br J Haematol
|
2007
|
2.09
|
|
9
|
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
|
J Clin Oncol
|
2002
|
1.75
|
|
10
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
|
Blood
|
2011
|
1.75
|
|
11
|
Role of interleukin 16 in multiple myeloma.
|
J Natl Cancer Inst
|
2012
|
1.62
|
|
12
|
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
|
Blood
|
2009
|
1.59
|
|
13
|
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
|
Bone
|
2008
|
1.44
|
|
14
|
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
|
J Clin Oncol
|
2013
|
1.39
|
|
15
|
Angiogenesis in multiple myeloma.
|
Eur J Cancer
|
2006
|
1.31
|
|
16
|
The potential of proteasome inhibitors in cancer therapy.
|
Expert Opin Investig Drugs
|
2008
|
1.31
|
|
17
|
Myeloma bone disease and proteasome inhibition therapies.
|
Blood
|
2007
|
1.29
|
|
18
|
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.
|
Eur J Haematol
|
2006
|
1.27
|
|
19
|
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.
|
Blood
|
2006
|
1.22
|
|
20
|
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
|
Eur J Haematol
|
2006
|
1.21
|
|
21
|
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
|
J Clin Oncol
|
2013
|
1.19
|
|
22
|
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
|
Haematologica
|
2006
|
1.16
|
|
23
|
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches.
|
Leuk Lymphoma
|
2010
|
1.14
|
|
24
|
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
|
Clin Cancer Res
|
2003
|
1.14
|
|
25
|
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.
|
Eur J Haematol
|
2008
|
1.13
|
|
26
|
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
|
Eur J Haematol
|
2007
|
1.11
|
|
27
|
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2003
|
1.11
|
|
28
|
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
|
Eur J Haematol
|
2008
|
1.10
|
|
29
|
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients.
|
J Clin Oncol
|
2003
|
1.09
|
|
30
|
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.
|
Biochem Biophys Res Commun
|
2005
|
1.07
|
|
31
|
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.
|
Eur J Cancer
|
2007
|
1.07
|
|
32
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.
|
Eur J Cancer
|
2008
|
1.07
|
|
33
|
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
|
Eur J Haematol
|
2009
|
1.05
|
|
34
|
Proteasome: an emerging target for cancer therapy.
|
Anticancer Drugs
|
2005
|
1.04
|
|
35
|
An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients.
|
Eur J Cancer
|
2010
|
1.03
|
|
36
|
Identification of clinically relevant yeasts by PCR/RFLP.
|
J Microbiol Methods
|
2004
|
1.02
|
|
37
|
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
|
Blood
|
2009
|
1.02
|
|
38
|
Gene expression profile of adult human bone marrow-derived mesenchymal stem cells stimulated by the chemokine CXCL7.
|
Int J Biochem Cell Biol
|
2008
|
1.01
|
|
39
|
Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.
|
Biochem Biophys Res Commun
|
2005
|
0.99
|
|
40
|
How to manage neutropenia in multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.98
|
|
41
|
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
|
Eur J Haematol
|
2009
|
0.96
|
|
42
|
Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists.
|
Pharmacogenetics
|
2004
|
0.94
|
|
43
|
Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.93
|
|
44
|
Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
|
Exp Cell Res
|
2007
|
0.93
|
|
45
|
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase.
|
J Cancer Res Clin Oncol
|
2008
|
0.93
|
|
46
|
Gene expression profiling of human mesenchymal stem cells chemotactically induced with CXCL12.
|
Cell Tissue Res
|
2009
|
0.92
|
|
47
|
mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitors.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.92
|
|
48
|
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
|
Leuk Lymphoma
|
2010
|
0.91
|
|
49
|
Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25.
|
Exp Cell Res
|
2009
|
0.91
|
|
50
|
Human bone marrow myeloma cells express RANKL.
|
J Clin Oncol
|
2002
|
0.91
|
|
51
|
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.
|
Br J Haematol
|
2007
|
0.90
|
|
52
|
Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma.
|
Eur J Haematol
|
2002
|
0.89
|
|
53
|
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
|
Eur J Haematol
|
2009
|
0.89
|
|
54
|
Immunocytochemistry reveals RANKL expression of myeloma cells.
|
Blood
|
2002
|
0.89
|
|
55
|
Novel anti-myeloma agents and angiogenesis.
|
Leuk Lymphoma
|
2008
|
0.87
|
|
56
|
Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.
|
Pharmacogenet Genomics
|
2007
|
0.87
|
|
57
|
Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy.
|
Nephrol Dial Transplant
|
2002
|
0.87
|
|
58
|
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
|
Ann Hematol
|
2003
|
0.86
|
|
59
|
The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.
|
Eur J Haematol
|
2012
|
0.86
|
|
60
|
Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.
|
J Cancer Res Clin Oncol
|
2004
|
0.86
|
|
61
|
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018).
|
Haematologica
|
2007
|
0.86
|
|
62
|
Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases.
|
Eur J Cancer
|
2009
|
0.86
|
|
63
|
Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.
|
Anticancer Drugs
|
2004
|
0.85
|
|
64
|
Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
|
J Cancer Res Clin Oncol
|
2003
|
0.85
|
|
65
|
Bone markers in multiple myeloma.
|
Eur J Cancer
|
2006
|
0.85
|
|
66
|
The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.
|
Eur J Haematol
|
2013
|
0.83
|
|
67
|
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
|
Anticancer Drugs
|
2006
|
0.82
|
|
68
|
Cross-cultural differences in information disclosure evaluated through the EORTC questionnaires.
|
Psychooncology
|
2011
|
0.81
|
|
69
|
Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.
|
Recent Results Cancer Res
|
2007
|
0.80
|
|
70
|
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.
|
J Cancer Res Clin Oncol
|
2003
|
0.80
|
|
71
|
[Interdisciplinary guidelines for diagnosis and therapy of extracerebral amyloidosis: issued by the German Society of Amyloid Diseases e. V. (www.amyloid.de)].
|
Med Klin (Munich)
|
2006
|
0.80
|
|
72
|
Serum levels of total-RANKL in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2009
|
0.79
|
|
73
|
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
|
Anticancer Drugs
|
2005
|
0.78
|
|
74
|
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.
|
Clin Dev Immunol
|
2011
|
0.78
|
|
75
|
Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
|
Eur J Haematol
|
2004
|
0.77
|
|
76
|
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
|
J Cancer Res Clin Oncol
|
2005
|
0.77
|
|
77
|
The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas.
|
Anticancer Drugs
|
2002
|
0.77
|
|
78
|
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.
|
Invest New Drugs
|
2005
|
0.77
|
|
79
|
Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography.
|
Clin Cancer Res
|
2003
|
0.77
|
|
80
|
Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
|
Exp Cell Res
|
2009
|
0.76
|
|
81
|
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
|
Eur J Haematol
|
2010
|
0.76
|
|
82
|
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.
|
Clin Dev Immunol
|
2012
|
0.76
|
|
83
|
Bisphosphonates in early multiple myeloma.
|
Eur J Haematol
|
2003
|
0.76
|
|
84
|
Chondrogenic differentiation of human mesenchymal stem cells in micro-masses is impaired by high doses of the chemokine CXCL7.
|
J Tissue Eng Regen Med
|
2011
|
0.75
|
|
85
|
Circulating hepatocyte growth factor levels in multiple myeloma.
|
Br J Haematol
|
2003
|
0.75
|
|
86
|
Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells.
|
Cancer Res
|
2004
|
0.75
|
|
87
|
Serum levels of VEGF do not correlate with the severity of multiple myeloma.
|
Br J Haematol
|
2002
|
0.75
|
|
88
|
Angiogenesis in multiple myeloma.
|
Leuk Res
|
2002
|
0.75
|
|
89
|
Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.
|
Anticancer Drugs
|
2003
|
0.75
|
|
90
|
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
|
Invest New Drugs
|
2005
|
0.75
|
|
91
|
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
92
|
Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.
|
Blood
|
2010
|
0.75
|
|
93
|
Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma--a phase II study.
|
Anticancer Drugs
|
2002
|
0.75
|
|
94
|
Information disclosure to cancer patients: EORTC QLQ-INFO25 questionnaire.
|
Expert Rev Pharmacoecon Outcomes Res
|
2011
|
0.75
|